Back to TLA

Search Results - ganga+reddy+velma

2 Results

Sort By:

Chimeric Inhibitors

Chimeric PARP/NAMPT inhibitors have been designed to be phosphoribosylated by NAMPT (nicotinamide phosphoribosyltransferase). This modification enriches the cytotoxic adducts held within cancer cells that overexpress NAMPT and significantly increases the safety and efficacy of PARP inhibition, minimizes resistance, and promotes further cancer cell death....

Published: 3/4/2026 | Updated: 3/4/2026 | Inventor(s): Gregory Thatcher, Jiqiang Fu, Ganga Reddy Velma

Keywords(s):

Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Oncology

Kinase Suppressors for Cancer Therapy

Mixed Lineage Kinase 3 (MLK3) has been identified as a promising target for cancer therapy, particularly for addressing aggressive cancers such as triple-negative breast cancer (TNBC). TNBC is a challenging cancer type with limited treatment options and disproportionately affects certain populations. This innovative technology focuses on a series of...

Published: 3/17/2025 | Updated: 3/17/2025 | Inventor(s): Gregory Thatcher, Ganga Reddy Velma, Rui Xiong

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Women's Health, Technology Classifications > Life Sciences > Small Molecules